Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Pasithea Therapeutics Corp.KTTA · Entity 7685 | Director · Chief Executive Officer | May 01, 2026 | May 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Pasithea Therapeutics Corp.
Report date May 01, 2026 · Filed May 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.84 · Expires 2036-04-30 | Direct | 1,756,069 |
Reported balance
After 2026-05-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-01 · Grant · Acquired 1,756,069 · Balance 1,756,069 F1: The option (the "Option") award was made in accordance with the terms of the Issuer's 2023 Stock Incentive Plan, as amended (the "Plan"). The shares of the Issuer's common stock, par value $0.0001 per share, underlying the Option will vest at the rate of 33% upon the one-year anniversary of the date of grant and the remaining shares will vest in equal quarterly installments thereafter for the next two years; provided, that the Reporting Person remains in continuous service to the Issuer through such vesting dates; provided further, that the shares underlying the Option will fully vest upon a Change in Control (as defined in the Plan). Additionally, all vested and exercisable shares underlying the Option held by the grantee may be exercised by the grantee for a period of up until three (3) years following termination of Continuous Service (as defined in the Plan), other than a termination for Cause (as defined in the Plan). |
Filing footnotes · ownership attribution and instrument terms
F1: The option (the "Option") award was made in accordance with the terms of the Issuer's 2023 Stock Incentive Plan, as amended (the "Plan"). The shares of the Issuer's common stock, par value $0.0001 per share, underlying the Option will vest at the rate of 33% upon the one-year anniversary of the date of grant and the remaining shares will vest in equal quarterly installments thereafter for the next two years; provided, that the Reporting Person remains in continuous service to the Issuer through such vesting dates; provided further, that the shares underlying the Option will fully vest upon a Change in Control (as defined in the Plan). Additionally, all vested and exercisable shares underlying the Option held by the grantee may be exercised by the grantee for a period of up until three (3) years following termination of Continuous Service (as defined in the Plan), other than a termination for Cause (as defined in the Plan).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 01, 2026 Filed May 5, 2026 20:42 UTC | Pasithea Therapeutics Corp. KTTA · Entity 7685 | GrantStock Option (right to buy) · Derivative | 1,756,069 | $0.00 Strike: $0.84 | $0.00 |
DisclosureSEC source: 0001213900-26-052262 · ownership.xml · derivative · entry 1 Marques Tiago · CIK 0001875240 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,756,069 Underlying: Common Stock · 1,756,069 shares Expires 2036-04-30 F1 · derivative.exercise_date: The option (the "Option") award was made in accordance with the terms of the Issuer's 2023 Stock Incentive Plan, as amended (the "Plan"). The shares of the Issuer's common stock, par value $0.0001 per share, underlying the Option will vest at the rate of 33% upon the one-year anniversary of the date of grant and the remaining shares will vest in equal quarterly installments thereafter for the next two years; provided, that the Reporting Person remains in continuous service to the Issuer through such vesting dates; provided further, that the shares underlying the Option will fully vest upon a Change in Control (as defined in the Plan). Additionally, all vested and exercisable shares underlying the Option held by the grantee may be exercised by the grantee for a period of up until three (3) years following termination of Continuous Service (as defined in the Plan), other than a termination for Cause (as defined in the Plan). Read SEC document |
| November 28, 2025 Filed Dec 1, 2025 13:56 UTC | Pasithea Therapeutics Corp. KTTA · Entity 7685 | PurchaseCommon Stock | 33,333 | $0.75 | $24,999.75 |
DisclosureSEC source: 0001213900-25-116301 · ownership.xml · nonDerivative · entry 1 Marques Tiago · CIK 0001875240 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,334 Read SEC document |
| October 24, 2025 Filed Oct 27, 2025 21:26 UTC | Pasithea Therapeutics Corp. KTTA · Entity 7685 | GrantStock Option (right to buy) · Derivative | 493,341 | $0.00 Strike: $0.72 | $0.00 |
DisclosureSEC source: 0001213900-25-102677 · ownership.xml · derivative · entry 1 Marques Tiago · CIK 0001875240 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 493,341 Underlying: Common Stock · 493,341 shares Expires 2035-10-23 F1 · derivative.exercise_date: The option (the "Option") award was made in accordance with the terms of the Issuer's 2023 Stock Incentive Plan, as amended (the "Plan"). The shares of the Issuer's common stock, par value $0.0001 per share, underlying the Option will vest at the rate of 33% upon the one-year anniversary of the date of grant and the remaining shares will vest in equal quarterly installments thereafter for the next two years; provided, that the Reporting Person remains in continuous service to the Issuer through such vesting dates; provided further, that the shares underlying the Option will fully vest upon a Change in Control (as defined in the Plan). Additionally, all vested and exercisable shares underlying the Option held by the grantee may be exercised by the grantee for a period of up until three (3) years following termination of Continuous Service (as defined in the Plan), other than a termination for Cause (as defined in the Plan). Read SEC document |
| May 12, 2025 Filed May 15, 2025 01:55 UTC | Pasithea Therapeutics Corp. KTTA · Entity 7685 | SaleCommon Stock | 960 | $0.83 | $792.00 |
DisclosureSEC source: 0001213900-25-043621 · ownership.xml · nonDerivative · entry 1 Marques Tiago · CIK 0001875240 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,001 F1 · shares: The Reporting Person previously held 960 shares of Common Stock of the Issuer in a foreign brokerage account that was recently wound down. As a result, the foreign broker automatically liquidated the Reportion Person's account on May 12, 2025 by selling the 960 shares of Common Stock of the Issuer on a non-discretionary basis. Read SEC document |
| March 01, 2024 Filed Mar 2, 2024 02:46 UTC | Pasithea Therapeutics Corp. KTTA · Entity 7685 | GrantStock Option (right to buy) · Derivative | 11,669 | $0.00 Strike: $8.34 | $0.00 |
DisclosureSEC source: 0001213900-24-019219 · ownership.xml · derivative · entry 2 Marques Tiago · CIK 0001875240 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,669 Underlying: Common Stock · 11,669 shares Expires 2034-02-28 F2 · derivative.exercise_date: The option award was made in accordance with the terms of the 2023 Plan. The option award fully vested upon issuance and became exercisable on March 1, 2024. Read SEC document |
| March 01, 2024 Filed Mar 2, 2024 02:46 UTC | Pasithea Therapeutics Corp. KTTA · Entity 7685 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $8.34 | $0.00 |
DisclosureSEC source: 0001213900-24-019219 · ownership.xml · derivative · entry 1 Marques Tiago · CIK 0001875240 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2034-02-28 F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's 2023 Stock Incentive Plan (the "2023 Plan"). The shares of the Issuer's common stock, par value $0.0001 per share ("Common Stock"), underlying the option award will vest at the rate of 33% upon the one-year anniversary of the date of grant and the remaining shares will vest in equal quarterly installments thereafter for the next two years; provided, that the Reporting Person remains a director or otherwise in continuous service to the Issuer through such vesting date. Read SEC document |
| March 01, 2024 Filed Apr 6, 2024 01:45 UTC Amendment | Pasithea Therapeutics Corp. KTTA · Entity 7685 | GrantStock Option (right to buy) · Derivative | 11,669 | $0.00 Strike: $8.13 | $0.00 |
DisclosureSEC source: 0001213900-24-030963 · ownership.xml · derivative · entry 2 Marques Tiago · CIK 0001875240 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,669 Underlying: Common Stock · 11,669 shares Expires 2034-02-28 F1 · derivative.exercise_price: The sole purpose of this Form 4/A is to correct the exercise price, which was previously reported erroneously as $8.34 per share. The correct exercise price, based upon the closing price of the Issuer's common stock, par value $0.0001 per share ("Common Stock"), on March 1, 2024, was $8.13 per share. F3 · derivative.exercise_date: The option award was made in accordance with the terms of the 2023 Plan. The option award fully vested upon issuance and became exercisable on March 1, 2024. Read SEC document |
| March 01, 2024 Filed Apr 6, 2024 01:45 UTC Amendment | Pasithea Therapeutics Corp. KTTA · Entity 7685 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $8.13 | $0.00 |
DisclosureSEC source: 0001213900-24-030963 · ownership.xml · derivative · entry 1 Marques Tiago · CIK 0001875240 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2034-02-28 F1 · derivative.exercise_price: The sole purpose of this Form 4/A is to correct the exercise price, which was previously reported erroneously as $8.34 per share. The correct exercise price, based upon the closing price of the Issuer's common stock, par value $0.0001 per share ("Common Stock"), on March 1, 2024, was $8.13 per share. F2 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's 2023 Stock Incentive Plan (the "2023 Plan"). The shares of Common Stock underlying the option award will vest at the rate of 33% upon the one-year anniversary of the date of grant and the remaining shares will vest in equal quarterly installments thereafter for the next two years; provided, that the Reporting Person remains a director or otherwise in continuous service to the Issuer through such vesting date. Read SEC document |
| November 25, 2022 Filed Nov 28, 2022 21:00 UTC | Pasithea Therapeutics Corp. KTTA · Entity 7685 | GrantCommon Stock | 2,000 | $1.03 | $2,060.00 |
DisclosureSEC source: 0001213900-22-075490 · ownership.xml · nonDerivative · entry 4 Marques Tiago · CIK 0001875240 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 819,206 Read SEC document |
| November 23, 2022 Filed Nov 28, 2022 21:00 UTC | Pasithea Therapeutics Corp. KTTA · Entity 7685 | GrantCommon Stock | 1,206 | $1.02 | $1,230.12 |
DisclosureSEC source: 0001213900-22-075490 · ownership.xml · nonDerivative · entry 3 Marques Tiago · CIK 0001875240 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 817,206 Read SEC document |
| November 23, 2022 Filed Nov 28, 2022 21:00 UTC | Pasithea Therapeutics Corp. KTTA · Entity 7685 | GrantCommon Stock | 1,000 | $1.03 | $1,030.00 |
DisclosureSEC source: 0001213900-22-075490 · ownership.xml · nonDerivative · entry 2 Marques Tiago · CIK 0001875240 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 816,000 Read SEC document |
| November 23, 2022 Filed Nov 28, 2022 21:00 UTC | Pasithea Therapeutics Corp. KTTA · Entity 7685 | GrantCommon Stock | 5,000 | $1.00 | $5,000.00 |
DisclosureSEC source: 0001213900-22-075490 · ownership.xml · nonDerivative · entry 1 Marques Tiago · CIK 0001875240 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 815,000 Read SEC document |
| October 21, 2022 Filed Oct 21, 2022 21:05 UTC | Pasithea Therapeutics Corp. KTTA · Entity 7685 | GrantCommon Stock | 4,400 | $1.07 | $4,708.00 |
DisclosureSEC source: 0001213900-22-065571 · ownership.xml · nonDerivative · entry 2 Marques Tiago · CIK 0001875240 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 810,000 Read SEC document |
| October 21, 2022 Filed Oct 21, 2022 21:05 UTC | Pasithea Therapeutics Corp. KTTA · Entity 7685 | GrantCommon Stock | 600 | $1.08 | $648.00 |
DisclosureSEC source: 0001213900-22-065571 · ownership.xml · nonDerivative · entry 1 Marques Tiago · CIK 0001875240 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 805,600 Read SEC document |
| June 23, 2022 Filed Jun 23, 2022 21:10 UTC | Pasithea Therapeutics Corp. KTTA · Entity 7685 | GrantCommon Stock | 1,800 | $0.99 | $1,789.20 |
DisclosureSEC source: 0001213900-22-034643 · ownership.xml · nonDerivative · entry 4 Marques Tiago · CIK 0001875240 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 805,000 Read SEC document |
| June 23, 2022 Filed Jun 23, 2022 21:10 UTC | Pasithea Therapeutics Corp. KTTA · Entity 7685 | GrantCommon Stock | 100 | $0.99 | $98.80 |
DisclosureSEC source: 0001213900-22-034643 · ownership.xml · nonDerivative · entry 3 Marques Tiago · CIK 0001875240 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 803,200 Read SEC document |
| June 23, 2022 Filed Jun 23, 2022 21:10 UTC | Pasithea Therapeutics Corp. KTTA · Entity 7685 | GrantCommon Stock | 200 | $0.98 | $196.40 |
DisclosureSEC source: 0001213900-22-034643 · ownership.xml · nonDerivative · entry 2 Marques Tiago · CIK 0001875240 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 803,100 Read SEC document |
| June 23, 2022 Filed Jun 23, 2022 21:10 UTC | Pasithea Therapeutics Corp. KTTA · Entity 7685 | GrantCommon Stock | 2,900 | $0.99 | $2,879.70 |
DisclosureSEC source: 0001213900-22-034643 · ownership.xml · nonDerivative · entry 1 Marques Tiago · CIK 0001875240 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 802,900 Read SEC document |
| December 20, 2021 Filed Dec 22, 2021 22:00 UTC | Pasithea Therapeutics Corp. KTTA · Entity 7685 | GrantStock Option (to acquire Common Stock) · Derivative | 200,000 | $0.00 Strike: $1.44 | $0.00 |
DisclosureSEC source: 0001213900-21-067062 · ownership.xml · derivative · entry 2 Marques Tiago · CIK 0001875240 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2031-12-20 F2 · derivative.exercise_date: The Reporting Person was granted 200,000 stock options. The stock options have a ten-year term and vest over three years, subject to Dr. Marques remaining employed and in good standing, one-third vesting 12 months after the grant date, and the remainder vesting in equal tranches quarterly for two years thereinafter. Read SEC document |
| December 20, 2021 Filed Dec 22, 2021 22:00 UTC | Pasithea Therapeutics Corp. KTTA · Entity 7685 | GrantCommon Stock | 200,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-21-067062 · ownership.xml · nonDerivative · entry 1 Marques Tiago · CIK 0001875240 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 800,000 F1 · security: The Reporting Person was granted Restricted Stock Units which shall vest into common stock of the Company over three years, subject to Dr. Marques remaining employed and in good standing, one-third vesting 12 months after the grant date, and the remainder vesting in equal tranches quarterly for two years thereinafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.